Despite preclinical promise, Dihexa's proposed mechanism of action, primarily via HGF/c-Met potentiation and synaptogenesis, rests on foundational data that has been retracted, requiring careful re-evaluation.
Dihexa, a synthetic hexapeptide derived from Angiotensin IV, has garnered considerable interest in the longevity and cognitive enhancement space. Preclinical studies, primarily in rodent models, have suggested its potential to promote synaptogenesis and improve cognitive function. However, a critical examination of the underlying evidence reveals significant limitations, particularly regarding its proposed mechanism of action and the complete absence of human clinical data. As editors, we consistently advocate for an evidence-first approach, and for Dihexa, the evidence base is, shall we say, complex.
Searches across PubMed, major medical journals like *Nature*, *NEJM*, and *JAMA*, as well as NIH and Cochrane Library trial registries, consistently show a complete lack of registered or completed human randomised controlled trials (RCTs) for Dihexa as of mid-2024, extending to at least 2026. This means we have no human data regarding efficacy, safety, optimal dosing, or long-term effects. Any claims of benefit for human use are, therefore, extrapolations from animal studies or anecdotal accounts, which simply do not meet the bar for evidence-based practice in healthspan optimisation.
Crucially, secondary summaries aimed at researchers explicitly state: “Dihexa improved cognition in rodent models; **no human trial has established a cognitive benefit, safe dose, side-effect rate, or long-term safety**.” This strongly implies that for anyone considering Dihexa, they are operating entirely without a safety net of human-specific empirical data. Quantitative human effect sizes, numbers needed to treat (NNT), numbers needed to harm (NNH), or long-term risk profiles are non-existent. Our /legal/disclaimer is particularly pertinent here.
The prevailing hypothesis posits Dihexa as a brain-penetrant Angiotensin IV analogue that primarily potentiates hepatocyte growth factor (HGF) signalling via its receptor, c-Met. This is a conceptually elegant mechanism: HGF and c-Met are known to be critical for brain development, neuronal survival, and synaptic plasticity. However, the foundational mechanistic biochemistry papers that defined Dihexa's HGF binding, equilibrium dissociation constant (Kd), c-Met phosphorylation, and cell scattering data were, regrettably, retracted in 2025. This retraction means that all quantitative claims and much of the initial characterisation of Dihexa's interaction with HGF and c-Met must be treated as provisional, if not entirely discredited, within the scientific community.
Despite these retractions, the general model maintains that Dihexa, a synthetic Angiotensin IV-derived peptide, exhibits strong blood-brain barrier penetration. It was reported to bind HGF with high affinity, and in low HGF conditions, to induce c-Met phosphorylation. The proposed action is that Dihexa binds to HGF itself, rather than directly to c-Met, thereby enhancing HGF’s ability to activate c-Met even at subthreshold HGF concentrations. Effectively, it was believed to act as an HGF potentiator rather than an independent agonist.
Downstream of c-Met activation, Dihexa was associated with canonical survival and plasticity pathways, notably PI3K/Akt and MAPK/ERK. These pathways are integral to cell proliferation, survival, and differentiation, including neuronal growth and synaptic remodelling. Across *in vitro* and rodent studies, Dihexa and similar Angiotensin IV analogues were linked to increased hippocampal spinogenesis and synaptogenesis – the formation of new dendritic spines and synapses – which are structural correlates of learning and memory. This is, in theory, how it would contribute to cognitive enhancement.
It is crucial to highlight the current expert consensus: "Dihexa’s proposed primary mechanism is potentiation of the hepatocyte growth factor (HGF) and its receptor c-Met… the two studies that first established this mechanism have since been retracted (see Research Limitations), so the HGF/c-Met model should be treated as a proposed rather than settled mechanism." (Source 1). This uncertainty underscores the provisional nature of much of what we thought we knew about Dihexa's core action. This is a point we frequently make in our research library – always follow the paper trail.
To reiterate, there are no human trial data for Dihexa. This means we have no information about how Dihexa might affect morning cortisol, HRV (rMSSD, 7-day avg), fasting glucose, hs-CRP, VO₂max, sleep efficiency, or subjective focus (1–10) in humans. While preclinical work often forms the basis for translational research, the complete absence of even Phase 1 safety trials means that Dihexa remains, from an evidence-based perspective, an experimental compound with an unconfirmed and possibly invalidated mechanism. Researchers utilise tools like our biomarker insights tool to track these parameters, but for Dihexa, there's simply no human data to interpret.
Animal studies, predominantly in rodent models, have reported improved learning and memory, enhanced neurogenesis, and increased synaptic density following Dihexa administration. For example, studies in rats with induced cognitive deficits (e.g., scopolamine-induced amnesia or aged rats) have shown benefits across various behavioural tasks. However, the leap from rodent models to human application is fraught with challenges, and many compounds that show promise in animals fail in human trials. The retraction of key mechanistic papers only compounds this issue, casting a shadow over the foundation of these preclinical observations.
Given the total absence of human trials, discussing effect sizes for Dihexa is impossible. We have no data to quantify any potential cognitive benefits or any impact on relevant biomarkers in humans. For example, we cannot say how Dihexa might influence subjective focus scores or impact parameters like sleep efficiency, which are commonly tracked in Executive Performance protocols.
In animal models, reported effects include significant increases in dendritic spine density and improvements in performance on mazes and memory tasks. However, these are measured in contexts specific to animal physiology and neuroanatomy. Without human studies, we cannot correlate these preclinical 'effect sizes' with any meaningful human healthspan or cognitive outcomes. Our standard approach at Longevity Stack is to look for robust, quantifiable changes in biomarkers that are linked to health outcomes. Dihexa offers none.
As with efficacy and mechanism, the safety profile of Dihexa in humans is entirely unknown. There is no information regarding common side effects, severe adverse events, drug interactions, or contraindications. In the United Kingdom, any substance without formal regulatory approval lacks the rigorous safety data required for public health recommendations. Given its proposed involvement with growth factor pathways, theoretical concerns could arise regarding unregulated cell proliferation, although this remains purely speculative in the absence of data.
Animal studies have not typically reported acute toxicity at doses used to elicit cognitive effects, but chronic safety data, especially pertaining to oncogenicity or neuroplasticity gone awry, is scarce even in animal models. Without human-specific pharmacokinetic and pharmacodynamic data, any use in humans carries inherent, unquantifiable risks. We simply do not know what the safe dose is, what the toxic dose is, or who should avoid it.
The practical implications for anyone considering Dihexa are straightforward and stark: there are no evidence-based protocols for human use. Dosing recommendations, administration routes, and expected outcomes are all derived from anecdotal reports or theoretical extrapolations from animal data. This positions Dihexa firmly outside the realm of evidence-based longevity or cognitive interventions. For those seeking genuine support for cognitive function, exploring compounds with established mechanisms and robust human clinical trials, such as various nootropics or established peptides with better safety profiles, would be a much more prudent approach. We've seen this play out time and again with promising compounds that never make the leap from preclinical to clinical application.
Its availability is often through research chemical vendors, which typically do not adhere to pharmaceutical-grade manufacturing standards, further compounding safety concerns regarding purity and concentration. In the UK, it is not available via regulated pharmacies or health stores like Boots or Holland & Barrett, reinforcing its status as a research chemical rather than a medicinal product.
Our editorial take on Dihexa is unequivocal: **skip it for now**. While the theoretical mechanism via HGF/c-Met potentiation is intriguing, the retraction of foundational mechanistic papers combined with the complete absence of human clinical data (safety, efficacy, dosing) makes any human use entirely unadvised. The mainstream view might highlight its preclinical promise; however, the data is messier. Until robust, peer-reviewed human trials demonstrate both safety and efficacy, and address the validity of its proposed mechanism, Dihexa remains a compound of academic interest only, not a viable tool for health optimisation. Your biomarkers and overall health are too important to base decisions on retracted science and purely anecdotal evidence.
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.